Trinity Biotech PLC (TRIB) intrinsic value & 10-year financials
Trinity Biotech PLC (TRIB) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue shrank 5.3% a year to $61.6M, with an average return on invested capital of 290.1%.
- Graham intrinsic value
- —
- Revenue (FY2024)
- $61.6M
- Revenue growth (10-yr CAGR)
- -5.3%
- ROIC (10-yr avg)
- 290.1%
- Free cash flow (FY2024)
- -$4.6M
TRIB 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2024 | $61.6M | -$31.2M | — | -$4.6M | — | 105.6% |
| FY2023 | $56.8M | -$36.9M | — | -$12.4M | — | 282.2% |
| FY2022 | $74.8M | -$41.0M | — | -$2.0M | — | 3286.7% |
| FY2021 | $93.0M | $929.0K | — | $11.4M | — | -73.2% |
| FY2020 | $102.0M | -$6.0M | — | $20.6M | — | -482.2% |
| FY2019 | $90.4M | -$29.0M | — | $3.3M | — | -118.9% |
| FY2018 | $97.0M | -$22.7M | — | -$299.0K | — | -41.5% |
| FY2017 | $99.1M | -$38.7M | — | $4.4M | — | -44.5% |
| FY2016 | $99.6M | -$38.6M | — | $6.0M | — | -23.9% |
| FY2015 | $100.2M | $22.2M | — | $6.1M | — | 10.4% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
TRINITY BIOTECH PLC is facing top-line stagnation, with revenue contracting over the decade.
TRINITY BIOTECH PLC has historically struggled to out-earn its cost of capital, averaging just -15.5% ROIC.
Over the decade, TRINITY BIOTECH PLC shows that the company has leveraged its balance sheet to sustain operations.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, TRINITY BIOTECH PLC is modeled at -5.3% normalized earnings growth with a 5.1% bond-yield adjustment.